1. Home
  2. BNTX

as of 04-28-2026 3:48pm EST

$101.87
$0.19
-0.19%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

Founded: 2008 Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 24.2B IPO Year: 2019
Target Price: $133.46 AVG Volume (30 days): 800.8K
Analyst Decision: Strong Buy Number of Analysts: 13
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $79.81 - $124.00 Next Earning Date: 05-05-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -20.35% Revenue Growth (next year): 3.37%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered BNTX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 68.57%
68.57%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of BioNTech SE (BNTX)

Poetting Sierk

Chief Operating Officer

Sell
BNTX Apr 22, 2026

Avg Cost/Share

$110.56

Shares

50,000

Total Value

$5,527,960.00

Owned After

399,387

SEC Form 4

Share on Social Networks: